Ramesh Ashwanth, Lyons Frank, Kelleher Michael
RCSI, Department of Anatomy, St. Stephens Green, Dublin 2, Ireland.
Cappagh National Orthopaedic Hospital, Dublin, Ireland.
Neurosurg Rev. 2016 Apr;39(2):197-205; discussion 205. doi: 10.1007/s10143-015-0664-9. Epub 2015 Sep 2.
With an aging population, degenerative lumbar spinal stenosis (DLSS) leading to neurogenic intermittent claudication (NIC) is a growing problem. For patients suffering from this condition, interspinous process distraction devices (IPDs) offer an effective and cheap alternative to conservative or decompressive surgery. Aperius is one such device that has been gaining popularity for its percutaneous insertion under local anesthetic, short operative time, and low risk of complications. The main objective of this review was to carry out a comprehensive search of the literature to evaluate the effectiveness and potential complications of Aperius. A database search, including PubMed, Clinical trials.gov, Cochrane (CENTRAL), MEDLINE, CINAHL, EMBASE, and Scopus, was carried out to identify relevant articles written in English reporting on complications with a minimum 12-month follow-up. The literature search resulted in six eligible studies; two nonrandomized comparative and four prospective case series were available. The analysis revealed that in total, 433 patients underwent treatment with Aperius, with all studies demonstrating an improvement in outcome measures. The average follow-up was 17 months with an overall complication rate of 10.62%. Overall, the quality of evidence is low, suggesting that currently, the evidence is not compelling and further prospective randomized trials including cost-effectiveness studies are required.
随着人口老龄化,导致神经源性间歇性跛行(NIC)的退变性腰椎管狭窄症(DLSS)问题日益严重。对于患有这种疾病的患者,棘突间撑开装置(IPD)为保守治疗或减压手术提供了一种有效且廉价的替代方案。Aperius就是这样一种装置,因其可在局部麻醉下经皮插入、手术时间短且并发症风险低而越来越受欢迎。本综述的主要目的是全面检索文献,以评估Aperius的有效性和潜在并发症。我们进行了数据库检索,包括PubMed、Clinical trials.gov、Cochrane(CENTRAL)、MEDLINE、CINAHL、EMBASE和Scopus,以识别用英文撰写的、报告了至少12个月随访期并发症情况的相关文章。文献检索得到了六项符合条件的研究;其中有两项非随机对照研究和四项前瞻性病例系列研究。分析显示,总共有433例患者接受了Aperius治疗,所有研究均表明治疗效果有所改善。平均随访时间为17个月,总体并发症发生率为10.62%。总体而言,证据质量较低,这表明目前证据并不充分,需要进一步开展包括成本效益研究在内的前瞻性随机试验。